Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis.

Medicine (Baltimore) · 2018 · PMC6081055 · PMID 30075504

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference did not reach statistical significance due to the limitation of sample size, we found that all the endpoints, including recurrence of VTE, incidence of major bleeding, and mortality were non-significantly lower in rivaroxaban group than in enoxaparin group.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.